Tumor Immunotherapy Medical Services in China

Immunotherapy for oncology represents a paradigm shift in cancer treatment, leveraging the body’s own immune system to recognize and eliminate malignant cells. Unlike conventional chemotherapy or radiation, which directly target tumors, immunotherapies—such as immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 agents like pembrolizumab and nivolumab), CAR-T cell therapy, cancer vaccines, and cytokine-based regimens—enhance T-cell activation, overcome tumor-induced immunosuppressionitumor responses. This approach has demonstrated remarkable efficacy in advanced melanoma, non-small cell lung cancer, renal cell carcinoma, lymphomas, and certain hematologic malignancies, with some patients achieving long-term rem response varies by tumor type, biomarker status (e.g., PD-L1 expression, tumor mutational burden), and individual immune competence—making precise patient selection and multidisciplinary evaluation essential.

China has emerged as a leading destination for immunotherapy due to its robust clinical research infrastructure, rapid regulatory approval of novel agents—including domestically developed PD-1 inhibitors (e.g., camrelizumab, sintilimab) with comparable efficacy and favorable safety profiles—and widespread integration of next-generation sequencing and liquid biopsy for biomarker-guided treatment. Leading oncology centers in Beijing, Shanghai, and Guangzhou report high response rates in real-world cohorts, particularly in NSCLC and hepatocellular carcinoma, supported by state-of-the-art-cell analysis, and GMP-compliant CAR-T manufacturing facilities. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising clinical rigor or regulatory oversight. As a dedicated medical tourism agency, we facilitate seamless access to these resources: coordinating appointments with NCCN- and E, verifying hospital accreditation and therapy eligibility, providing itemized, transparent pricing in advance, and delivering end assistance and medical translation to post-treatment follow-up coordination.

Treatment Options & Itemized Cost Breakdown: Tumor Immunotherapy (Oncology Department)

Non-Surgical / Medication-Based Immunotherapies

*Eligibility*: Confirmed solid or hematologic malignancy with PD-L1 expression ≥1% (IHC), MSI-H/dMMR status, or specific biomarker eligibility (e.g., NTRK fusion); ECOG PS ≤2; adequate organ function.

• •PD-1/PD-L1 Inhibitors (e.g., Pembrolizumab, Camrelizumab, Sintilimab)

- *Baseline biomarker testing (PD-L1 IHC + MSI/MMR PCR)*: $240 - *Monthly labs (CBC, LFTs, TSH, cortisol)*: $65/cycle - *CT/MRI surveillance (q8–12 weeks)*: $420–$580/study

• •CTLA-4 + PD-1 Dual Checkpoint Blockade (e.g., Ipilimumab + Nivolumab)

- *Maintenance PD-1 monotherapy (q4w)*: $2,100–$3,400/cycle - *Autoimmune toxicity monitoring (adrenal panel, stool calprotectin, colonoscopy if colitis suspected)*: $180–$390 per episode

Surgical/Procedural/Interventional Immunotherapy Support

*Eligibility*: Resectable tumor with high immunogenic potential (e.g., melanoma, RCC, NSCLC stage IB–IIIA); no contraindications to surgery or perioperative immunotherapy.

• •Neoadjuvant Immunotherapy (pre-op, 2–4 cycles)

- *Preoperative workup (EKG, pulmonary function, enhanced CT/PET-CT, cardiac echo if indicated)*: $1,150–$1,720

• •Adjuvant Immunotherapy (post-op, up to 1 year)

- *Surgical pathology review + tumor mutational burden (TMB) assay*: $310

Special/Complex Condition Options

• •CAR-T Therapy (for relapsed/refractory B-cell lymphoma or multiple myeloma)

- *Pre-CAR-T lymphodepletion (Fludarabine/Cyclophosphamide)*: $1,450 - *ICANS/CRS management (tocilizumab, corticosteroids, ICU support)*: $3,200–$9,800

• •Tumor-Infiltrating Lymphocytemelanoma, cervical cancer – investigational but clinically available at select centers)

• •<60 years, fit, high-risk resectable NSCLC: Neoadjuvant nivolumab + surgery ($10,200–$16,300 total) — optimal balance of efficacy and cost.
• •Age 75+, limitedCLC PD-L1 ≥50%: Single-agent camrelizumab ($1,850/cycle; $22,200/year) — lower toxicity, predictable cost.
• •Relapsed DLBCL after 2 lines: CAR-T ($128,000+) — only curative option; requires ≥$100K budget or insurance coverage.
• •MSI-H colorectal cancer, multiple comorbidities: Pembrolizumab monotherapy ($2,900/cycle) — avoids chemo toxicity, lowest monitoring burden.
• •Severe autoimmune disease (e.g., active RA, IBD): Avoid CTLA-4; use PD-1 inhibitor + rigorous rheumatology co-management (+$480/month consult fee).